Does the media favor ZTS or BMY?

In the previous week, Bristol Myers Squibb had 8 more articles in the media than Zoetis. MarketBeat recorded 52 mentions for Bristol Myers Squibb and 44 mentions for Zoetis. Bristol Myers Squibb's average media sentiment score of 1.21 beat Zoetis' score of 0.74 indicating that Bristol Myers Squibb is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zoetis 22 Very Positive mention(s) 0 Positive mention(s) 21 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Bristol Myers Squibb 39 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Which has stronger earnings & valuation, RPRX or ZTS?

Zoetis has higher revenue and earnings than Royalty Pharma. Zoetis is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Royalty Pharma $2.38B 12.82 $770.95M $1.47 36.03 Zoetis $9.47B 3.48 $2.67B $6.03 13.05

Is RPRX or ZTS more profitable?

Royalty Pharma has a net margin of 33.88% compared to Zoetis' net margin of 27.80%. Zoetis' return on equity of 66.85% beat Royalty Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Royalty Pharma 33.88% 29.25% 14.71% Zoetis 27.80% 66.85% 18.79%

Does the media prefer RPRX or ZTS?

In the previous week, Zoetis had 35 more articles in the media than Royalty Pharma. MarketBeat recorded 44 mentions for Zoetis and 9 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 1.58 beat Zoetis' score of 0.74 indicating that Royalty Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Royalty Pharma 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Zoetis 22 Very Positive mention(s) 0 Positive mention(s) 21 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media favor ZTS or JAZZ?

In the previous week, Zoetis had 22 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 44 mentions for Zoetis and 22 mentions for Jazz Pharmaceuticals. Zoetis' average media sentiment score of 0.74 beat Jazz Pharmaceuticals' score of 0.58 indicating that Zoetis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zoetis 22 Very Positive mention(s) 0 Positive mention(s) 21 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Jazz Pharmaceuticals 11 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive

Which has stronger valuation & earnings, ZTS or CORT?

Zoetis has higher revenue and earnings than Corcept Therapeutics. Zoetis is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zoetis $9.47B 3.48 $2.67B $6.03 13.05 Corcept Therapeutics $761.41M 11.27 $99.65M $0.35 228.31

Does the media favor ZTS or CORT?

In the previous week, Zoetis had 25 more articles in the media than Corcept Therapeutics. MarketBeat recorded 44 mentions for Zoetis and 19 mentions for Corcept Therapeutics. Zoetis' average media sentiment score of 0.74 beat Corcept Therapeutics' score of 0.52 indicating that Zoetis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zoetis 22 Very Positive mention(s) 0 Positive mention(s) 21 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Corcept Therapeutics 7 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SUPN or ZTS?

In the previous week, Zoetis had 41 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 44 mentions for Zoetis and 3 mentions for Supernus Pharmaceuticals. Zoetis' average media sentiment score of 0.74 beat Supernus Pharmaceuticals' score of 0.28 indicating that Zoetis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Supernus Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zoetis 22 Very Positive mention(s) 0 Positive mention(s) 21 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Zoetis (ZTS) Competitors

$78.69 -0.02 (-0.03%)

Closing price 06/18/2026 03:59 PM Eastern

Extended Trading

$78.70 +0.01 (+0.01%)

As of 06/18/2026 07:58 PM Eastern

Compare

ZTS vs. BMY, RPRX, JAZZ, CORT, and SUPN

Should you buy Zoetis stock or one of its competitors? MarketBeat compares Zoetis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Zoetis include Bristol Myers Squibb (BMY), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Corcept Therapeutics (CORT), and Supernus Pharmaceuticals (SUPN). These companies are all part of the "pharmaceuticals" industry.

How does Zoetis compare to Bristol Myers Squibb?

Zoetis (NYSE:ZTS) and Bristol Myers Squibb (NYSE:BMY) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Zoetis presently has a consensus target price of $133.92, indicating a potential upside of 70.18%. Bristol Myers Squibb has a consensus target price of $61.31, indicating a potential upside of 13.33%. Given Zoetis' higher possible upside, equities analysts plainly believe Zoetis is more favorable than Bristol Myers Squibb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zoetis	1 Sell rating(s)	8 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.33
Bristol Myers Squibb	1 Sell rating(s)	10 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.37

Bristol Myers Squibb has higher revenue and earnings than Zoetis. Zoetis is trading at a lower price-to-earnings ratio than Bristol Myers Squibb, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zoetis	$9.47B	3.48	$2.67B	$6.03	13.05
Bristol Myers Squibb	$48.19B	2.29	$7.05B	$3.56	15.20

92.8% of Zoetis shares are owned by institutional investors. Comparatively, 76.4% of Bristol Myers Squibb shares are owned by institutional investors. 0.2% of Zoetis shares are owned by insiders. Comparatively, 0.1% of Bristol Myers Squibb shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Zoetis pays an annual dividend of $2.12 per share and has a dividend yield of 2.7%. Bristol Myers Squibb pays an annual dividend of $2.52 per share and has a dividend yield of 4.7%. Zoetis pays out 35.2% of its earnings in the form of a dividend. Bristol Myers Squibb pays out 70.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Zoetis has increased its dividend for 14 consecutive years and Bristol Myers Squibb has increased its dividend for 17 consecutive years. Bristol Myers Squibb is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Zoetis has a net margin of 27.80% compared to Bristol Myers Squibb's net margin of 15.01%. Zoetis' return on equity of 66.85% beat Bristol Myers Squibb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zoetis	27.80%	66.85%	18.79%
Bristol Myers Squibb	15.01%	64.87%	13.16%

Zoetis has a beta of 0.75, meaning that its share price is 25% less volatile than the broader market. Comparatively, Bristol Myers Squibb has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market.

In the previous week, Bristol Myers Squibb had 8 more articles in the media than Zoetis. MarketBeat recorded 52 mentions for Bristol Myers Squibb and 44 mentions for Zoetis. Bristol Myers Squibb's average media sentiment score of 1.21 beat Zoetis' score of 0.74 indicating that Bristol Myers Squibb is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zoetis	22 Very Positive mention(s)	0 Positive mention(s)	21 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Bristol Myers Squibb	39 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Zoetis beats Bristol Myers Squibb on 10 of the 19 factors compared between the two stocks.

How does Zoetis compare to Royalty Pharma?

Royalty Pharma (NASDAQ:RPRX) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, valuation, earnings, analyst recommendations, institutional ownership and profitability.

54.4% of Royalty Pharma shares are owned by institutional investors. Comparatively, 92.8% of Zoetis shares are owned by institutional investors. 18.8% of Royalty Pharma shares are owned by company insiders. Comparatively, 0.2% of Zoetis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Royalty Pharma has a beta of 0.43, meaning that its share price is 57% less volatile than the broader market. Comparatively, Zoetis has a beta of 0.75, meaning that its share price is 25% less volatile than the broader market.

Royalty Pharma presently has a consensus price target of $53.71, suggesting a potential upside of 1.42%. Zoetis has a consensus price target of $133.92, suggesting a potential upside of 70.18%. Given Zoetis' higher probable upside, analysts clearly believe Zoetis is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00
Zoetis	1 Sell rating(s)	8 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.33

Royalty Pharma has a net margin of 33.88% compared to Zoetis' net margin of 27.80%. Zoetis' return on equity of 66.85% beat Royalty Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Royalty Pharma	33.88%	29.25%	14.71%
Zoetis	27.80%	66.85%	18.79%

Royalty Pharma pays an annual dividend of $0.94 per share and has a dividend yield of 1.8%. Zoetis pays an annual dividend of $2.12 per share and has a dividend yield of 2.7%. Royalty Pharma pays out 63.9% of its earnings in the form of a dividend. Zoetis pays out 35.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Royalty Pharma has increased its dividend for 5 consecutive years and Zoetis has increased its dividend for 14 consecutive years. Zoetis is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Zoetis has higher revenue and earnings than Royalty Pharma. Zoetis is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Royalty Pharma	$2.38B	12.82	$770.95M	$1.47	36.03
Zoetis	$9.47B	3.48	$2.67B	$6.03	13.05

In the previous week, Zoetis had 35 more articles in the media than Royalty Pharma. MarketBeat recorded 44 mentions for Zoetis and 9 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 1.58 beat Zoetis' score of 0.74 indicating that Royalty Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Royalty Pharma	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Zoetis	22 Very Positive mention(s)	0 Positive mention(s)	21 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Zoetis beats Royalty Pharma on 12 of the 19 factors compared between the two stocks.

How does Zoetis compare to Jazz Pharmaceuticals?

Zoetis (NYSE:ZTS) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

In the previous week, Zoetis had 22 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 44 mentions for Zoetis and 22 mentions for Jazz Pharmaceuticals. Zoetis' average media sentiment score of 0.74 beat Jazz Pharmaceuticals' score of 0.58 indicating that Zoetis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zoetis	22 Very Positive mention(s)	0 Positive mention(s)	21 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Jazz Pharmaceuticals	11 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive

92.8% of Zoetis shares are held by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are held by institutional investors. 0.2% of Zoetis shares are held by insiders. Comparatively, 4.1% of Jazz Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Zoetis has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market. Comparatively, Jazz Pharmaceuticals has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market.

Zoetis has higher revenue and earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zoetis	$9.47B	3.48	$2.67B	$6.03	13.05
Jazz Pharmaceuticals	$4.27B	3.31	-$356.15M	-$0.02	N/A

Zoetis currently has a consensus price target of $133.92, suggesting a potential upside of 70.18%. Jazz Pharmaceuticals has a consensus price target of $246.06, suggesting a potential upside of 9.52%. Given Zoetis' higher probable upside, equities research analysts plainly believe Zoetis is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zoetis	1 Sell rating(s)	8 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.33
Jazz Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.79

Zoetis has a net margin of 27.80% compared to Jazz Pharmaceuticals' net margin of 0.66%. Zoetis' return on equity of 66.85% beat Jazz Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zoetis	27.80%	66.85%	18.79%
Jazz Pharmaceuticals	0.66%	14.56%	5.25%

Summary

Zoetis beats Jazz Pharmaceuticals on 13 of the 16 factors compared between the two stocks.

How does Zoetis compare to Corcept Therapeutics?

Zoetis (NYSE:ZTS) and Corcept Therapeutics (NASDAQ:CORT) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.

Zoetis has higher revenue and earnings than Corcept Therapeutics. Zoetis is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zoetis	$9.47B	3.48	$2.67B	$6.03	13.05
Corcept Therapeutics	$761.41M	11.27	$99.65M	$0.35	228.31

Zoetis has a net margin of 27.80% compared to Corcept Therapeutics' net margin of 6.14%. Zoetis' return on equity of 66.85% beat Corcept Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zoetis	27.80%	66.85%	18.79%
Corcept Therapeutics	6.14%	7.40%	5.76%

In the previous week, Zoetis had 25 more articles in the media than Corcept Therapeutics. MarketBeat recorded 44 mentions for Zoetis and 19 mentions for Corcept Therapeutics. Zoetis' average media sentiment score of 0.74 beat Corcept Therapeutics' score of 0.52 indicating that Zoetis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zoetis	22 Very Positive mention(s)	0 Positive mention(s)	21 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Corcept Therapeutics	7 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

92.8% of Zoetis shares are owned by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are owned by institutional investors. 0.2% of Zoetis shares are owned by company insiders. Comparatively, 20.7% of Corcept Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Zoetis has a beta of 0.75, suggesting that its stock price is 25% less volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market.

Zoetis presently has a consensus target price of $133.92, suggesting a potential upside of 70.18%. Corcept Therapeutics has a consensus target price of $88.83, suggesting a potential upside of 11.17%. Given Zoetis' higher probable upside, equities research analysts plainly believe Zoetis is more favorable than Corcept Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zoetis	1 Sell rating(s)	8 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.33
Corcept Therapeutics	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Zoetis beats Corcept Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Zoetis compare to Supernus Pharmaceuticals?

Supernus Pharmaceuticals (NASDAQ:SUPN) and Zoetis (NYSE:ZTS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation.

Supernus Pharmaceuticals has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market. Comparatively, Zoetis has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market.

Zoetis has a net margin of 27.80% compared to Supernus Pharmaceuticals' net margin of -3.74%. Zoetis' return on equity of 66.85% beat Supernus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Supernus Pharmaceuticals	-3.74%	13.07%	9.66%
Zoetis	27.80%	66.85%	18.79%

In the previous week, Zoetis had 41 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 44 mentions for Zoetis and 3 mentions for Supernus Pharmaceuticals. Zoetis' average media sentiment score of 0.74 beat Supernus Pharmaceuticals' score of 0.28 indicating that Zoetis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Supernus Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zoetis	22 Very Positive mention(s)	0 Positive mention(s)	21 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

92.8% of Zoetis shares are owned by institutional investors. 8.5% of Supernus Pharmaceuticals shares are owned by insiders. Comparatively, 0.2% of Zoetis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Zoetis has higher revenue and earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Supernus Pharmaceuticals	$718.95M	3.58	-$38.55M	-$0.51	N/A
Zoetis	$9.47B	3.48	$2.67B	$6.03	13.05

Supernus Pharmaceuticals presently has a consensus price target of $62.17, indicating a potential upside of 40.08%. Zoetis has a consensus price target of $133.92, indicating a potential upside of 70.18%. Given Zoetis' higher probable upside, analysts plainly believe Zoetis is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Zoetis	1 Sell rating(s)	8 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Zoetis beats Supernus Pharmaceuticals on 13 of the 16 factors compared between the two stocks.

Get Zoetis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZTS vs. The Competition

Export

Metric	Zoetis	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$33.00B	$2.98B	$6.43B	$23.20B
Dividend Yield	2.69%	1.78%	2.68%	4.06%
P/E Ratio	13.05	18.67	24.75	31.61
Price / Sales	3.48	310.39	529.79	112.07
Price / Cash	10.40	56.42	45.07	24.44
Price / Book	10.41	4.04	10.80	4.68
Net Income	$2.67B	$75.79M	$3.57B	$1.08B
7 Day Performance	-1.04%	0.38%	0.72%	-0.82%
1 Month Performance	-1.79%	-0.14%	0.41%	1.07%
1 Year Performance	-49.96%	26.02%	29.34%	25.02%

Zoetis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZTS Zoetis	4.9771 of 5 stars	$78.69 0.0%	$133.92 +70.2%	-50.0%	$33.00B	$9.47B	13.05	14,500	Trending News High Trading Volume
BMY Bristol Myers Squibb	4.8229 of 5 stars	$56.30 -1.4%	$61.31 +8.9%	+15.4%	$114.97B	$48.48B	15.82	32,500	Positive News Dividend Announcement Gap Up
RPRX Royalty Pharma	4.6279 of 5 stars	$54.27 -1.1%	$53.71 -1.0%	+51.9%	$31.25B	$2.38B	36.92	80	Positive News Gap Up
JAZZ Jazz Pharmaceuticals	3.6698 of 5 stars	$230.59 +0.0%	$246.06 +6.7%	+109.0%	$14.49B	$4.44B	N/A	2,890	Insider Trade
CORT Corcept Therapeutics	3.7408 of 5 stars	$83.12 +0.3%	$88.83 +6.9%	+12.0%	$8.92B	$761.41M	237.49	300	Insider Trade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ZTS) was last updated on 6/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zoetis (ZTS) Competitors

ZTS vs. BMY, RPRX, JAZZ, CORT, and SUPN

How does Zoetis compare to Bristol Myers Squibb?

Summary

How does Zoetis compare to Royalty Pharma?

Summary

How does Zoetis compare to Jazz Pharmaceuticals?

Summary

How does Zoetis compare to Corcept Therapeutics?

Summary

How does Zoetis compare to Supernus Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZTS vs. The Competition

Zoetis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zoetis (ZTS) Competitors

ZTS vs. BMY, RPRX, JAZZ, CORT, and SUPN

How does Zoetis compare to Bristol Myers Squibb?

Do analysts rate ZTS or BMY?

Which has better valuation and earnings, ZTS or BMY?

Do insiders and institutionals hold more shares of ZTS or BMY?

Is ZTS or BMY a better dividend stock?

Is ZTS or BMY more profitable?

Which has more volatility & risk, ZTS or BMY?

Does the media favor ZTS or BMY?

Summary

How does Zoetis compare to Royalty Pharma?

Do institutionals & insiders have more ownership in RPRX or ZTS?

Which has more volatility & risk, RPRX or ZTS?

Do analysts recommend RPRX or ZTS?

Is RPRX or ZTS more profitable?

Is RPRX or ZTS a better dividend stock?

Which has stronger earnings & valuation, RPRX or ZTS?

Does the media prefer RPRX or ZTS?

Summary

How does Zoetis compare to Jazz Pharmaceuticals?

Does the media favor ZTS or JAZZ?

Do insiders and institutionals hold more shares of ZTS or JAZZ?

Which has more volatility & risk, ZTS or JAZZ?

Which has stronger earnings and valuation, ZTS or JAZZ?

Do analysts recommend ZTS or JAZZ?

Is ZTS or JAZZ more profitable?

Summary

How does Zoetis compare to Corcept Therapeutics?

Which has stronger valuation & earnings, ZTS or CORT?

Is ZTS or CORT more profitable?

Does the media favor ZTS or CORT?

Do insiders & institutionals hold more shares of ZTS or CORT?

Which has more risk & volatility, ZTS or CORT?

Do analysts rate ZTS or CORT?

Summary

How does Zoetis compare to Supernus Pharmaceuticals?

Which has more risk & volatility, SUPN or ZTS?

Is SUPN or ZTS more profitable?

Does the media prefer SUPN or ZTS?

Do insiders & institutionals believe in SUPN or ZTS?

Which has higher valuation & earnings, SUPN or ZTS?

Do analysts rate SUPN or ZTS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZTS vs. The Competition

Zoetis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools